Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

BACKGROUND: CT-P16 is a candidate bevacizumab biosimilar. OBJECTIVE: This double-blind, multicenter, parallel-group, phase III study aimed to establish equivalent efficacy between CT-P16 and European Union-approved reference bevacizumab (EU-bevacizumab) in patients with metastatic or recurrent non-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschraegen, Claire, Andric, Zoran, Moiseenko, Fedor, Makharadze, Tamta, Shevnya, Sergii, Oleksiienko, Alona, Yañez Ruiz, Eduardo, Kim, SungHyun, Ahn, KeumYoung, Park, TaeHong, Park, Sijin, Ju, Hana, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649513/
https://www.ncbi.nlm.nih.gov/pubmed/36169807
http://dx.doi.org/10.1007/s40259-022-00552-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649513/
https://www.ncbi.nlm.nih.gov/pubmed/36169807
http://dx.doi.org/10.1007/s40259-022-00552-8

Ejemplares similares